RxDoctor Payments Data

Lia Zappala, PA

Surgical · Whittier, CANPI 1851998579

Payments from drug & device makers

$984in general payments, 2019–2025

Across 15 payments — averaging $65.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$158
  • Axonics, Inc.$158
  • Urogen Pharma, Inc.$131
  • Olympus America Inc.$129
  • Sumitomo Pharma America, Inc.$85
  • Intuitive Surgical$83
  • plus $240 from 5 others

What the payments were for

  • Food & beverage$984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$984 in reported general payments places this provider in the 65th percentile of 729 surgical providers in California.

See all surgical providers in California

Medicare billing

Part B allowed, 2024
$24,554
Medicare patients
136
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron44$27,183
GemtesaVibegron14$8,854
Tamsulosin Hcl142$2,095
Methenamine Hippurate17$1,590
Solifenacin Succinate21$1,315
NitrofurantoinNitrofurantoin Macrocrystal39$1,276
Estradiol20$1,244
Finasteride78$1,101
Cephalexin47$526
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$398
Terazosin Hcl12$333
Ciprofloxacin Hcl60$236
Oxybutynin Chloride ErOxybutynin Chloride15$191
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$147
Oxybutynin Chloride14$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$80$27,18344 claims
Sumitomo Pharma America, Inc.Gemtesa$85$8,85414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 surgical providers in California.

Other surgical in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →